P621 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn’s disease patients: results from the EVOLVE study
Brian Bressler(University of British Columbia), Andrés Yarur(Cedars-Sinai Medical Center), Gerassimos J. Mantzaris(European CanCer Organisation), Petros Zezos(Mount Sinai Hospital), Dirk Demuth(Takeda (Singapore)), Dan J. Stein(University of Cape Town), Haridarshan Patel(Amgen (United States)), Chris Colby(Kaiser Permanente), C. Lopez(Takeda (United States)), T Lissoos(Takeda (United States)), Mark S. Silverberg(Sinai Health System), Athanasios Natsios(Municipality of Athens Development Agency), Gabriela Radulescu(Smithsonian Institution)
Cited by 8
Related Papers
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k